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Abstract The adult attention-deficit/hyperactivity disor-
der (ADHD) quality-of-life (AAQoL) scale was previously
validated in adult patients in the USA; here, the AAQoL is
validated in adult European patients. Data from a 12-week
open-label acute treatment period with atomoxetine
(80–100 mg/day) in adults with ADHD were used. Patients
(C18 to B50 years old) had a score C2 on C6 items on the
inattentive or hyperactive core subscales of Conners’ Adult
ADHD Rating Scale-Investigator Rated: Screening Version
(CAARS-Inv:SV); a CAARS-Inv:SV 18-item total ADHD
symptom score C20; and Conners’ Adult ADHD Rating
Scale-Observer: Screening Version 6-item inattentive or
hyperactive core subscale scores C2. Data were stratified
based on patients’ geographic region (Europe vs USA).
Scale validation psychometric properties results were very
similar between European (n = 1,217; 57.7 % male; mean
age 33.0 years) and US (n = 602; 62.1 % male; mean age
33.5 years) patients, including factor loading, internal
consistency, convergent and discriminant validity, and
responsiveness. Exploratory factor analysis confirmed four
AAQoL subscales. Internal consistency was acceptable
(Cronbach’s alpha[ 0.70 for all subscales). The AAQoL
total score showed moderate convergent validity with
CAARS-Inv:SV 18-item total ADHD symptom and clini-
cal global impression-ADHD-severity (CGI-ADHD-S)
scores; and strong convergent validity with Behavior Rat-
ing Inventory of Executive Function—Adult Version: Self-
Report Global-Executive-Composite Index scores. Mean
AAQoL total scores were significantly different among
patients grouped by CGI-ADHD-S scores, suggesting good
discriminant validity. The AAQoL total and subscale
scores presented good responsiveness from baseline to
12 weeks. The AAQoL scale shows comparable validity in
European and US adults with ADHD.
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Background
Effects of attention-deficit/hyperactivity disorder (ADHD)
in adults go beyond symptoms of inattention, hyperactivity,
and impulsivity that characterize the disorder (Adler et al.
2008; Matza et al. 2011). The impact of ADHD involves
many aspects of the patient’s life, such as lack of organi-
zation, difficulty concentrating, forgetfulness, greater
employment disruption, lower academic achievement,
difficulty initiating and maintaining relationships, and poor
driving behaviors (Adler et al. 2008). It has been shown
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that ADHD is associated with increased psychological
dysfunction and disability, significant job impairment, drug
and alcohol misuse, family conflicts, violence, traffic vio-
lations, and accidents (Adler et al. 2009). Not surprisingly,
patients with ADHD report lower quality-of-life (QoL)
than healthy comparison subjects, and the severity of
ADHD symptoms is negatively correlated with measures of
QoL (Adler et al. 2009; Mattos et al. 2012). Moreover, at
least in children with ADHD, the overall impact of the
disease is comparable to other major psychiatric disorders
or to severe physical conditions (Biederman et al. 2006a;
Danckaerts et al. 2010).
The adult ADHD quality-of-life (AAQoL) scale assesses
QoL in adult patients with ADHD (Brod et al. 2006). It was
developed based on qualitative data on the impact of
ADHD on everyday activities as reported by patients and
experts, as well as information collected from the scientific
literature (Mattos et al. 2011). The AAQoL scale devel-
opment followed the industry guidance ‘‘Patient-Reported
Outcome Measures: Use in Medical Product Development
to Support Labeling Claims’’ set by the Food and Drug
Administration (http://www.fda.gov/downloads/Drugs/Gui
danceComplianceRegulatoryInformation/Guidances/UCM
193282.pdf.). In 2006, the AAQoL was first validated in a
retrospective cohort study conducted in the USA that
included adult patients with ADHD (n = 989) treated with
atomoxetine. Psychometric validation results showed the
ability of the AAQoL to quantify the QoL consequences
of ADHD (Brod et al. 2006).
While the AAQoL has been validated and successfully
used in adult US patients with ADHD, validation data in
European patients are lacking. Here, we examine the
validity of the AAQoL in adult European patients with
ADHD treated with atomoxetine. We compare our results
with data from adult US patients with ADHD treated with
atomoxetine who participated in the same clinical trial.
Methods
This manuscript presents the results of secondary analyses
of clinical trial data from an open-label treatment period,
focusing on the validation of the AAQoL as a measurement
scale in adult European patients with ADHD. The results of
the primary study objective, examining the maintenance of
response to atomoxetine compared with placebo in adult
patients with ADHD, were published elsewhere (Up-
adhyaya et al. 2013a, b).
Study design
Data were used from a Phase 3, randomized, double-blind
maintenance-of-response trial of atomoxetine (80–100 mg/
day) versus placebo in adult outpatients with ADHD. Data
were used from the open-label treatment phase of the
study, during which all enrolled patients received treatment
with atomoxetine (starting dose: 40 mg/day; target dose:
80 or 100 mg/day) for 12 weeks. The study was conducted
in 152 centers across 18 countries. For the current analyses,
only data collected during the 12-week open-label treat-
ment period in 50 centers in the US and in 82 centers in
European countries were used. European countries inclu-
ded Austria, Belgium, Denmark, Finland, France, Ger-
many, Italy, the Netherlands, Portugal, Spain, Sweden,
Switzerland, and the UK. Data from additional non-Euro-
pean study centers located in Argentina, Canada, Mexico,
and Russia were not included in the present analyses.
Patients
Adults (C18 to B50 years old) of either gender with a
current and historical diagnosis of ADHD, as defined by
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text RevisionTM (DSM-IV-TRTM) criteria
and a score of C2 on at least 6 items of either the inat-
tentive or hyperactive core subscales of the Conners’ Adult
ADHD Rating Scale-Investigator Rated: Screening Version
(CAARS-Inv:SV) with adult ADHD prompts, were enrol-
led. In addition, patients had a CAARS-Inv:SV total
ADHD symptom score of C20, a score of C2 on at least 6
items of either the inattentive or hyperactive core subscales
of conners’ adult attention-deficit/hyperactivity disorder
rating scale-observer: screening version (CAARS-O:SV),
and a score of C4 on the CGI-ADHD-S. Excluded were
patients who met full DSM-IV-TR diagnostic criteria for
any history of bipolar disorder, current major depression, a
current anxiety disorder (including generalized anxiety
disorder, panic disorder, or social phobia), or any history of
a psychotic disorder (confirmed by the structured inter-
view); patients with HAMD-17 or HAMA scores of C15;
and patients with organic brain disease.
Rating scales
In the current analyses, four different rating scales assess-
ing disease severity were included—the AAQoL, the CA-
ARS-Inv:SV total ADHD symptom scale, the CGI-ADHD-
S scale, and the Behavior Rating Inventory of Executive
Function—Adult Version: Self-Report (BRIEF-A) scale.
All scales were translated using well-recognized scientific
guidelines for translation of patient-reported outcome
measures (Lohr et al. 1996) and administered in 11 dif-
ferent languages (Danish, Dutch, English, Finnish, French,
German, Italian, Portuguese, Russian, Spanish, and Swed-
ish), with the language of the scale depending on the pre-
valent language(s) of the patients’ country of residence.
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The AAQoL is a 29-item questionnaire designed to
assess QoL and was a secondary efficacy measure in this
trial (access information: www.thebrodgroup.net). It
includes four domains (subscale scores): (1) Life Produc-
tivity (11 items), including ‘‘getting things done on time,’’
‘‘completing projects or tasks,’’ ‘‘remembering important
things,’’ and ‘‘balancing multiple projects;’’ (2) Psycho-
logical Health (6 items), including ‘‘feeling anxious,’’
‘‘overwhelmed,’’ and ‘‘fatigued;’’ (3) Relationships (5
items), including ‘‘tension,’’ ‘‘annoyance,’’ and ‘‘frustration
in relationships;’’ (4) Life Outlook (7 items), including
‘‘perceptions that energy is well spent,’’ ‘‘people enjoy
spending time with you,’’ ‘‘you can successfully manage
your life,’’ and ‘‘you are as productive as you would like to
be.’’ Each item is rated by patients on a 5-point Likert scale
ranging from ‘‘Not at all/Never’’ (1) to ‘‘Extremely/Very
Often’’ (5). To derive overall and subscale scores, item
scores are transformed to a 0–100-point scale. Then, the
item scores are summed up and divided by item count to
generate subscale and overall scores. If[1 item of a sub-
score was missing, the subscore was treated as missing. If
[3 items for the overall score were missing, the overall
score was treated as missing (HCP Team: http://www.
hcplive.com/publications/DIALOGS-ADHD/2007/Jun2007/
Dialogs_ADHD_Quality_of_Life.). A higher score indicates
greater QoL (Brod et al. 2006).
The CAARS-Inv:SV total ADHD symptom scale and
the CGI-ADHD-S scale were used as primary efficacy
measures in this trial. The CAARS-Inv:SV total ADHD
symptom scale consists of the Inattention and Hyper-
activity/Impulsivity subscales of the CAARS-Inv:SV. The
CAARS-Inv:SV is a 30-item scale containing three sub-
scales: the Inattention subscale (items 1, 9, 13, 14, 19, 21,
26, 29, and 30), the Hyperactivity/Impulsivity subscale
(items 2, 4, 6, 8, 16, 18, 22, 25, and 27), and the ADHD
Index (items 3, 5, 7, 10, 11, 12, 15, 17, 20, 23, 24, and 28)
(Conners et al. 1999). Each item on the CAARS-Inv:SV
assesses symptom severity over the previous week and is
scored on a 0–3 scale (0 = not at all, never; 1 = just a
little, once in a while; 2 = pretty much, often; 3 = very
much, very frequently). Adult ADHD prompts were
embedded into the 18 items for the total ADHD symptom
score (Upadhyaya et al. 2013a). An ADHD symptom was
considered to be present if the score on the corresponding
item was C2. The scale was scored by qualified raters
based on interviews with the patients.
The CGI-ADHD-S is a single-item scale. It is rated
based on the clinician’s assessment of the overall severity
of the patient’s ADHD in relation to the clinician’s total
experience (National Institute of Mental Health 1985; Guy
1976). Severity is rated on a 7-point scale (1 = normal or
not at all ill; 2 = borderline mentally ill; 3 = mildly ill;
4 = moderately ill; 5 = markedly ill; 6 = severely ill;
7 = extremely ill).
The BRIEF-A was a secondary efficacy measure in this
trial. The BRIEF-A is a standardized self-report measure
that captures adults’ views of their own executive func-
tions, or self-regulation, in their everyday environments
(Roth et al. 2005). It is comprised of 75 equivalent items
within nine non-overlapping theoretically and empirically
derived clinical scales that measure different aspects of
executive functioning: inhibit, shift, emotional control,
self-monitor, initiate, working memory, plan/organize, task
monitor, and organization of materials. The individual
clinical scales form two broader indices: Behavioral Reg-
ulation Index and Metacognition Index. These indices form
the overall summary score, the Global-Executive-Compo-
site (GEC) Index.
Statistical analyses
Data from all European and US patients who enrolled in
the 12-week open-label treatment phase were included in
the analyses. Data were analyzed in three groups: European
patient group, US patient group, as well as both groups
combined. To analyze the data, statistical software SAS
version 9.1.3 (Cary, NC) was used.
Exploratory factor analysis
An exploratory factor analysis was used to examine the
underlying constructs of the AAQoL in the European
patient group and the US patient group. The number of
factors (4) examined in the analysis was based upon the
known number of AAQoL subscales, and a value of C0.30
was deemed to indicate successful factor loading (Cron-
bach 1951). Principal-components analysis with varimax
rotation was used to estimate the factor loadings and, in
turn, determine the underlying factor structure of this
study’s AAQoL items in European and US patient groups
(Reid 1995).
Internal consistency
The degree to which each item of a rating scale co-varies is
captured by measures of internal consistency. Internal
consistency for the AAQoL total and subscale scores was
assessed at baseline and week 12 by use of Cronbach’s
alpha (a), a measure of the average correlation of items
within a scale (Cronbach 1951). Cronbach’s a ranges from
0 to 1, with higher scores indicating greater internal con-
sistency. A commonly accepted minimal standard for
internal consistency is a Cronbach’s a of 0.65 (Zhang et al.
2005). When comparing groups, Cronbach’s a values of
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0.70–0.80 are regarded as satisfactory (Bland and Altman
1997).
Convergent validity
Convergent validity estimates the degree to which any two
measures that assess the same or similar entities are related
to each other (Stratford et al. 1996). Convergent validity
between AAQoL total score and CAARS-Inv:SV total
ADHD symptom score, CGI-ADHD-S score, and BRIEF-
A GEC Index score was assessed at week 12 using Pearson
correlation coefficients. In an exploratory analysis, Pearson
correlation coefficients of AAQoL subscale scores versus
AAQoL total scores, CAARS-Inv:SV, hyperactive/impul-
sive and inattentive scores, CGI-ADHD-S score, and
BRIEF-A Metacognition, Behavioral Regulation, and GEC
Index scores at week 12 were determined. Week 12 was
the last non-missing value during the 12-week open-label
acute treatment period.
Convergent validity was assessed with Pearson corre-
lation coefficients. In the current analyses, correlations
with a coefficient value B0.5 were classified as weak; those
with a correlation coefficient of[0.5 but\0.8 as moderate;
and those with a correlation coefficient of C0.8 as strong.
Discriminant validity
Discriminant validity indicates the ability to discriminate
between dissimilar constructs (Stratford et al. 1996)—here,
the ability of a scale to discriminate between patient groups
with differences in their QoL was assessed. A measure for
QoL in patients with ADHD should distinguish between
patients with different levels of QoL. Here, comparisons of
AAQoL total scores between patients grouped by CGI-
ADHD-S scores at 12 weeks, indicating severity of the
disease, were performed. Mean AAQoL total scores were
compared between patients with CGI-ADHD-S scores of 1
(normal) versus patients with CGI-ADHD-S scores of 2
through 5 (borderline mentally ill up to markedly ill;
5 = highest CGI-ADHD-S score at week 12 with a suffi-
cient number of affected patients to produce statistically
meaningful results). An analysis of variance was conducted
using AAQoL total score as the outcome and CGI-ADHD-
S as the predictor; P values were obtained by pairwise
comparison.
Responsiveness
Responsiveness is the extent to which a health status
measure accurately reflects change in a patient’s condition
over time (Matza et al. 2007). The standardized response
mean (SRM) is a unitless statistic summarizing
responsiveness, defined as the mean change from baseline
score divided by the standard deviation of the change
scores (Biederman et al. 2006b), similar in concept to
effect sizes, but using only data from one treatment group.
Wilcoxon signed-rank tests were used to assess within-
group changes from baseline to week 12 for the AAQoL
total and subscale scores based on clinical assessment of
improvement as measured by the CGI-ADHD-S.
Results
Patient demographics
A total of 1,819 adult patients with ADHD were considered
for this analysis. Among them, 1,217 patients resided in
European countries and 602 patients lived in the US.
Baseline demographic and clinical characteristics are pre-
sented in Table 1. Further comparisons of baseline patient
characteristics between European and non-European
patients were published previously (Upadhyaya et al.
2013a).
Exploratory factor analysis
Exploratory factor analysis loaded all AAQoL items onto
their previously reported subscales (Brod et al. 2006) with
the exception of item #29 (your intimate relationship is
going well emotionally), which loaded on the Relationships
subscale instead of the Life Outlook subscale. Loading and
significance of loading were very similar between Euro-
pean and US patients for all items including item #29
(Table 2).
Internal consistency
Cronbach’s a, a measure of internal consistency, at base-
line, was 0.744 for AAQoL total scores in European
patients and 0.771 in US patients; at week 12, Cronbach’s
a was 0.835 in European patients and 0.851 in US patients.
The internal consistency score improved from baseline to
week 12 in response to treatment with atomoxetine in both
European and US patients. For all four AAQoL subscales
(Life Productivity, Psychological Health, Life Outlook, and
Relationships), Cronbach’s a values were[0.70 at baseline
and week 12, indicating acceptable internal consistency in
European and US patients.
Overall, very similar values for Cronbach’s a were
observed for European and US patients. Internal consis-
tency remained high and acceptable with Cronbach’s
a[ 0.70 when patients from European and US groups
were combined, at both baseline and week 12 (Table 3).
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Convergent validity
As assessed with Pearson correlation coefficients, at
12 weeks, AAQoL total scores demonstrated moderate con-
vergent validity with CAARS-Inv:SV total ADHD symptom
and CGI-ADHD-S scores, in both European and US patient
populations. Correlations between AAQoL total scores and
BRIEF-A GEC Index scores were strong in both European
and US patient populations (Supplemental Table 1).
Overall, European and US patient populations showed
very similar correlation values between AAQoL total
scores and CAARS-Inv:SV total ADHD symptom scores,
CGI-ADHD-S scores, and BRIEF-A GEC Index scores,
indicating very similar convergent validity in European and
US patient groups (Supplemental Table 1).
In an exploratory analysis, Pearson correlation coefficients
between AAQoL subscale scores and AAQoL total scores as
well as CAARS-Inv:SV hyperactive/impulsive score, CA-
ARS-Inv:SV inattentive score, CGI-ADHD-S score, BRIEF-
A Metacognition Index score, BRIEF-A Behavioral Regula-
tion Index score, and BRIEF-AGEC Index score at 12 weeks
were assessed (Supplemental Table 1).
All four AAQoL subscale scores had moderate-to-
strong correlations with the AAQoL total score in
European and US patients. Correlations with the CA-
ARS-Inv:SV hyperactive/impulsive subscale score were
weak for all AAQoL subscale scores in European and
US patient groups. For the CAARS-Inv:SV inattentive
subscale, correlations with AAQoL subscale scores were













body mass index; CAARS-







countries, N total number of
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Age [years, mean (SD)] 33.0 (9.2) 33.5 (8.9) 33.2 (9.1) 0.29a
Race [n (%)] \0.001b
Caucasian 1,192 (97.9) 486 (80.7) 1,678 (92.2)
African 5 (0.4) 50 (8.3) 55 (3.0)
Hispanic 9 (0.7) 44 (7.3) 53 (2.9)
Native American 1 (0.1) 5 (0.8) 6 (0.3)
East Asian 3 (0.2) 11 (1.8) 14 (0.8)
West Asian (Indian subcontinent) 7 (0.6) 5 (0.8) 12 (0.7)
Not provided 0 (0.0) 1 (0.2) 1 (0.1)
Gender [n (%)] 0.08b
Male 702 (57.7) 374 (62.1) 1,076 (59.2)
Female 515 (42.3) 228 (37.9) 743 (40.8)
Body weight [kg, mean (SD)] 76.8 (17.6) 84.1 (19.3) 79.2 (18.5) \0.001a
Height [cm, mean (SD)] 173.8 (9.3) 172.3 (10.0) 173.3 (9.6) 0.002a
BMI [kg/m2, mean (SD)] 25.3 (5.0) 28.3 (5.9) 26.3 (5.5) \0.001a
ADHD subtype [n (%)] \0.001b
Inattentive 298 (24.5) 115 (19.1) 413 (22.7)
Hyperactive/impulsive 40 (3.3) 4 (0.7) 44 (2.4)
Combined 872 (71.7) 482 (80.1) 1,354 (74.4)
Not applicable 1 (0.1) 0 (0.0) 1 (0.1)
CGI-ADHD-S score [mean (SD)] 5.1 (0.8) 4.6 (0.6) 5.0 (0.8) \0.001a
CAARS-Inv:SV score [mean (SD)]
Hyperactivity–Impulsivity subscale
imputed
17.4 (5.2) 18.3 (4.9) 17.7 (5.1) \0.001a
Inattention subscale imputed 20.9 (3.6) 21.6 (3.6) 21.1 (3.6) \0.001a
Total ADHD symptom imputed 38.3(6.7) 39.9(6.8) 38.8(6.8) \0.001a
AAQoL [mean (SD)]
Total score imputed 47.6 (14.3) 48.0 (14.0) 47.7 (14.2) 0.53a
Psychological Health section score 51.4 (20.9) 53.1 (19.2) 52.0 (20.3) 0.09a
Relationships section score 53.6 (21.2) 52.8 (19.1) 53.3 (20.5) 0.44a
Life Outlook section score 45.1 (17.0) 52.5 (14.9) 47.6 (16.7) \0.001a
Life Productivity section score 44.2 (18.1) 40.3 (19.0) 42.9 (18.5) \0.001a
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All AAQoL subscale scores showed weak correlations
with the CGI-ADHD-S score with the exception of the
Life Productivity subscale, which demonstrated moder-
ate correlation with the CGI-ADHD-S score in both
European and US patients. The AAQoL Productivity
subscale score was also moderately correlated with both
the BRIEF-A Metacognition Index score and the BRIEF-
A GEC Index score. For the remaining 3 AAQoL sub-
scales, scores were low moderately correlated with the
BRIEF-A Metacognition Index score and the BRIEF-A
Table 2 Exploratory factor











of-life, EC European countries,
n number of patients with a
baseline value, US United States
a Item #29 loaded in our study
for European and US groups on
the AAQoL Relationships
subscale instead of AAQoL Life
Outlook subscale. This may be
due to the fact that conceptually
the item could belong to both
Life Outlook and Relationships
subscales









1 Keep the house/apartment clean or
uncluttered
0.620 0.651 0.627
2 Manage your finances (such as cashing
checks, balancing your checkbook, paying
bills on time)
0.553 0.596 0.582
3 Remember important things 0.562 0.686 0.624
4 Get your shopping done (such as for food,
clothes, or household items)
0.514 0.621 0.576
5 Pay attention when interacting with others 0.417 0.588 0.507
11 Getting things done requires too much effort 0.569 0.613 0.554
22 Complete projects or tasks (either at work or
at home)
0.758 0.721 0.739
23 Get started with tasks you do not find
interesting
0.686 0.685 0.678
24 Balance multiple projects 0.647 0.672 0.661
25 Get things done on time 0.764 0.719 0.733





6 Overwhelmed 0.463 0.634 0.518
7 Anxious 0.725 0.741 0.731
8 Depressed 0.700 0.728 0.721
13 You have overreacted in difficult or stressful
situations
0.394 0.321 0.421
20 Feeling fatigued 0.603 0.514 0.584
21 Fluctuations (ups and downs) in your
emotions
0.671 0.674 0.703
Life outlook 14 Your energy is well spent (has positive
results)
0.703 0.703 0.713
15 Able to enjoy time spent with others 0.644 0.550 0.618
16 You can successfully manage your life 0.700 0.655 0.693
17 As productive as you would like to be 0.683 0.646 0.664
27 Good about yourself 0.666 0.633 0.678
28 People enjoy spending time with you 0.521 0.597 0.541
29a Your intimate relationship is going well
emotionally
0.155 0.018 0.091
Relationships 9 You have not been able to meet others’
expectations of you (either at home or at
work)
0.364 0.305 0.333
10 You annoyed people 0.731 0.662 0.716
12 People are frustrated with you 0.710 0.637 0.697
18 Tension in relationships 0.556 0.569 0.515
19 Not having quality time to spend with others 0.391 0.566 0.394
29a Your intimate relationship is going well
emotionally
-0.306 -0.268 -0.306
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GEC Index score. Correlations between all AAQoL
subscale scores and the BRIEF-A Behavioral Regulation
Index score were low-moderate to moderate in European
and US patient groups (Supplemental Table 1). Overall,
correlations between AAQoL subscale scores and com-
parator scale scores were very similar in European and
US patient groups.
Discriminant validity
Overall, discriminant validity (measured with analysis of var-
iance)was very similar betweenEuropean andUSgroups, with
comparable mean AAQoL scores for patient groups with
identical CGI-ADHD-S scores. Mean AAQoL total scores
decreased with increasing CGI-ADHD-S scores in European
and US patients, indicating lower QoL in patients with higher
ADHD symptom severity. Furthermore, analyses revealed
significant (P B 0.0001 for European and US patient groups)
differences in mean AAQoL total scores at week 12 between
patients with a CGI-ADHD-S score of 1 versus patients with
CGI-ADHD-S scores of 2 through 5, indicating discriminant
validity of the AAQoL (Fig. 1; too few patients had CGI-
ADHD-S scores[5 at week 12 for statistically meaningful
analyses).
Responsiveness
The AAQoL total and subscale scores showed significant
(Wilcoxon signed-rank tests, P\ 0.001) mean changes
from baseline to week 12 in European and US patient
groups, indicating good responsiveness.
Mean AAQoL total and subscale score changes were
similar between European and US patient groups. Addi-
tionally, SRMs were comparable between European and
US patient groups (Table 4), indicating similar respon-
siveness in European and US patient groups.
Discussion
The analyses presented here provide evidence that the
AAQoL is a valid measure of ADHD-related QoL in adult
European patients. While the AAQoL has previously been
validated in US patients, this is the first validation of the
Table 3 Internal consistency as represented by AAQoL subscales: Cronbach’s Alpha at baseline and week 12
Variable category EC US EC ? US
Baseline Week 12 Baseline Week 12 Baseline Week 12




























































European countries include: Austria, Belgium, Denmark, Finland, France, Germany, Italy, the Netherlands, Portugal, Spain, Sweden, Swit-
zerland, and the UK
AAQoL adult attention-deficit/hyperactivity disorder quality-of-life, EC European countries, n number of patients, US United States
Fig. 1 Comparison of AAQoL total scores and CGI-ADHD-S scores
at week 12. AAQoL adult attention-deficit/hyperactivity disorder
quality-of-life, CGI-ADHD-S clinical global impression attention-
deficit/hyperactivity disorder-severity, EC European countries, n num-
ber of subjects, US United States
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AAQoL in European patients. Although this clinical trial
was not designed to test the validity of the AAQoL, it
allowed a comparative validation of the scale in one sub-
population (European patients) versus another subpopula-
tion (US patients) in which the AAQoL had been
previously validated. Overall, results of all measures for
internal consistency, convergent and discriminant validity,
and responsiveness were very similar between regions
within our study, as well as between our study populations
and a prior validation of the AAQoL (Brod et al. 2006).
The exploratory factor analysis confirmed the valid
discrimination of four AAQoL subscales in European and
US patient groups, with similar loading values for all items
in European and US patients. With the exception of item
#29 (your intimate relationship is going well emotionally),
the previously published (Brod et al. 2006) factor structure
was confirmed in European and US patients. Item #29
loaded for European and US patients on the AAQoL
Relationships subscale; previously, it has been reported to
belong to the AAQoL Life Outlook subscale. While it is
not surprising that item #29 originally loaded on the Life
Outlook subscale, as it refers to a positive perspective in
the patient’s life, it is also not surprising that it could load
on the Relationships subscale, as it specifically refers to the
quality of the patient’s relationship. Conceptually, item #29
could be in either Life Outlook or Relationships subscales.
The AAQoL demonstrated acceptable internal consis-
tency at both baseline and week 12 with Cronbach’s a
values of[0.70 for total and subscale scores in European
and US patient populations, which is consistent with prior
findings (Brod et al. 2006).
Convergent validity of the AAQoL total score at week
12 was weak to moderate with the CAARS-Inv:SV total
ADHD symptom score and the CGI-ADHD-S score and
was moderate to strong with the BRIEF-A GEC Index
score. These findings are consistent with the fact that the
AAQoL was created to specifically address the impact of
ADHD symptoms on the life of patients, and some of its
questions overlap with questions targeting ADHD symp-
toms or impairment caused by ADHD in the patients. The
moderate-to-strong correlation between the AAQoL and
the BRIEF-A GEC Index is also not surprising, as deficits
in executive functioning have been demonstrated to be an
essential abnormality in ADHD (Coghill 2010). Moreover,
it is expected that deficits in executive functioning, which
are impairments that the individual has on planning,
organizing, and executing practical tasks in life would be
associated with a worse perception of QoL.
As expected, all correlation values between AAQoL and
comparator scale scores were negative due to the scale
definitions: A higher score on the AAQoL indicates better
life functioning, while lower scores on the comparator
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Discriminant validity was assessed by measuring the
ability of the AAQoL to discriminate among patients
grouped by their week 12 CGI-ADHD-S scores, because no
scale that would be suitable for the assessment of dis-
criminant validity was included in the clinical trial.
Therefore, we chose to address discriminant validity as the
ability of the AAQoL to discriminate between different
levels of ADHD severity. For European and US patients,
mean AAQoL scores were significantly different between
patients with a CGI-ADHD-S score of 1, indicating men-
tally normal, versus patients with CGI-ADHD-S scores of
2–5, indicating borderline mentally ill up to markedly ill.
This suggests that the AAQoL was able to discriminate
groups of patients with different disease severity. Overall,
results for discriminant validity were very similar between
European and US patient groups.
These findings suggest that the AAQoL is a valuable
tool to assess treatment effects in clinical trials, addressing
an important need in the field. Within the ADHD research
community, an increasing demand to incorporate assess-
ments of treatment effects that go beyond pure symptom-
atic amelioration is being recognized (Coghill 2010). Poor
QoL has been identified as an important dimension to be
evaluated when assessing treatment effects in clinical tri-
als. The similar responsiveness in European and US patient
groups suggests that the AAQoL is an adequate tool for
evaluating treatment effects in both geographic regions.
While the tool is primarily used in clinical trials, it might
also be useful for clinical practitioners when assessing
treatment success in their adult patients.
Overall, the moderate correlation between the AAQOL
and the CAARS-Inv:SV supports the idea that the 18-item
total ADHD symptom score listed in the Diagnostic and
Statistical Manual of Mental Disorders (DSM) does not
capture the full impact of ADHD on QoL. Consequently,
QoL assessment at baseline and during treatment is of
much importance. Both DSM symptoms and QoL should
be assessed to demonstrate improvement in patients with
ADHD, as expressed in the European Medical Agency
(EMA) guidelines for drug development in ADHD.
The interpretation of the results of the current study is
limited by the open-label study design. Because this study
was not designed for a priori investigation of psychometric
properties of the AAQoL in a European population, the
scales that were chosen as comparators for convergent and
discriminant validity were not the standard scales that
could be used for that purpose. However, psychometric
findings in European and US patient populations in this
study were overall very consistent. Together with the prior
validation study of the AAQoL in a US population (Brod
et al. 2006), the current results suggest that the AAQoL can
be used as an adequate measure of QoL in European and
US patients. Strengths of the study are the use of a patient
population which well represents diverse European regions
and the inclusion of a US population in which the AAQoL
has previously been validated.
Conclusions
The AAQoL shows comparable validity in European and
US patients, C18 to B50 years old, for assessing baseline
and changes in QoL in adults with ADHD during treatment
with atomoxetine. Based on our results, the AAQoL can be
a valuable tool to investigate QoL in European adult
patients with ADHD and can be used to measure changes
in the QoL with treatment in these patients.
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